Theralase Technologies Inc. V.TLT

one article - new today

[DJDawg]

https://www.urotoday.com/conference-highlights/aua-2023/aua-2023-bladder-cancer/144093-aua-2023-an-interim-analysis-of-a-phase-ii-clinical-study-of-intravesical-photo-dynamic-therapy-in-patients-with-bcg-unresponsive-non-muscle-invasive-bladder-cancer-nmibc-carcinoma-in-situ-cis.html

[Alamir1111]

Good info. Most patients 21% were heavily pretreated with bcg up to 19 procedure.s Wow We should be front page.

[stocksnbonds458]

One fine day we will be front page news

[tdon1229]

Meanwhile, have a look at today's action on IMGN (ImmunoGen) with its ADC approach to platinum-reistant ovarian cancer...and dream of our day yet to come.

[ScienceFirst]

IMGN is up +130% (to 2.7B$US) on this phase 3 ovarian news mostly because shorts got caught pants down having to run.  That's confirmed by the 93M+ shares traded, when the TSO has 226M ones.   But again, such 2B$+US validates the valuation of a future SOC.   One day, we get there if we get full approval.  And so far, we have the data to get there.  We just need to

[ScienceFirst]

  ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer IMGN | 9 hours ago   Results Show Statistically Significant Improvements in PFS, ORR, and OS Compared to Chemotherapy First Medicine to Demonstrate an Overall Survival

[ScienceFirst]

This helps assess what type of benefits a future SOC brings on the table, so we can be confident with our case, even though the example below is in another indication.   Key Findings from MIRASOL MIRASOL enrolled 453 patients; 14% had one prior line of therapy, 39% had two prior lines of therapy, and 47% had three prior lines of therapy. 62% of patients received prior bevacizumab; 55

[DeathXray33]

Oldie but Goodie: Theralase Anti-Cancer Drugs Effective in the Destruction of Cervical Cancer Tuesday, September 5, 2017 7:00 AM Theralase Technologies Inc. https://theralase.com/   Share this Article TORONTO, ONTARIO / ACCESSWIRE / September 5, 2017 / Theralase Technologies Inc. ("Theralase®" or the

[ScienceFirst]

I told you such article would come.  My guess is that we will get additional visibility from in-depth coverage now that this official AUA article is out. Interesting perspectives: Most patients were heavily pre-treated with BCG. 21% had > 19 treatments in the past.

[Alamir1111]

Intersting 70% Cis cancer inside bladder 10%Cis+ta inermost layer of bladder 20% cis+t1 starting to grow in to connective tissue beneath bladder lining. That ads a little bit more challenge .

[Alamir1111]

Looks like the screning proces of selecting patients is prety good.Today article didn't  mention urethral cancer  no pipes are infected.nor cis+t2  which is muscle . This might explain the slover enrolment process.

[Alamir1111]

Looks like tlt is 100% focused on task

[Alamir1111]

Rdw is an engiener .arguing with them is like pissing in a electric conduct.they have plans. Scientists have vision  of  future. Now combine this together  not bad. Add a Kevin  shark to mix  much better

[consultant99]

Since most if not all patients that Theralase treats have already had numerous BCG treatments it begs the question 'do the BCG treatments have any impact positively or negatively on our success rate'? There doesn't seem to have been any noticable impact on the share price from the recent conference which is disappointing.

[BlueFranky]

Yep That's me - concurring with you

[StevenBirch]

Articles while nice will not move the stock price. 

[Oden6570]

Well for whatever reason TLT is avoiding self promotion of any kind IMHO. So many unanswered questions again IMHO.  Is a deal already done  ? No insider buying since November 2022 ! Coincidence ? What is going on in the vaccine front ? Is a CEO change on the horizon ? It is my opinion that if TLT was located in the US are poor weakened sp would be much higher than. 23 cents. What are

[CancerSlayer]

  It looks like they are taking a more cautious approach in terms of promotion/getting the word out.  You probably don't want to oversell potential on relatively limited trial data pre-BTD...jmo.  There needs to be an effective option that not only works, but one that is patient-friendly, doesn't break the bank & can be more easily accessible (i.e. more easily

[CancerSlayer]

Correction has been highlighted: It looks like they are taking a more cautious approach in terms of promotion/getting the word out.  You probably don't want to oversell potential on relatively limited trial data pre-BTD...jmo.  There needs to be an effective option that not only works, but one that is patient-friendly, doesn't break the bank & can be more easily

[Alamir1111]

When big pharma  shows up to do a jv or a buyout they are only interested in one thing what can they get  to incorporate in their gene editing tech.Rest goes in recycling bin. 

[Longholder99]

They suffered enough with the OSC jumping on their backs over the cold laser.  If I'm the BOD in this situation.  I'm not saying anything.  Whoever put in that completely targeted and purposeful complaint is to blame for any SP weakness we have suffered these past few years.  Not the management at TLT.  They achieved their goal of keeping us in the toilet and our

[CancerSlayer]

Thanks Dawg.... There was also a comparison study presented by Dr.Wei Shen Tan that looked at early bladder removal for high-risk BCG-unresponsive NMIBC vs the use of bladder-sparing treatments.  He found no significant difference with regards to overall survival & cancer-specific survival between the two groups.  This simply provides further proof that bladder-sparing treatment

[Rumpl3StiltSkin]

I pray myself, or anyone I know, never gets cancer(too late) Yet if they do, I hope it is NMIBC. I think TLT has this one figured out. And I'd start this protocol early, forget BCG...